Top Markets
Coin of the day
Baudax Bio, Inc. Baudax Bio, Inc.

Baudax Bio, Inc.

BXRXQ
Rang in Aktien #42133
Baudax Bio, Inc., a biotechnology company, develops and commercializes products... Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$4.36K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
9,900.00%
Land
US
Handel Baudax Bio, Inc. (BXRXQ)

Kategorie

Dividendenrendite-Verlauf für Baudax Bio, Inc. (BXRXQ)
Dividendenrendite (TTM) von Baudax Bio, Inc. (Aktienkürzel: BXRXQ) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Baudax Bio, Inc. (BXRXQ) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber